UA117466C2 - СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 - Google Patents

СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Info

Publication number
UA117466C2
UA117466C2 UAA201506824A UAA201506824A UA117466C2 UA 117466 C2 UA117466 C2 UA 117466C2 UA A201506824 A UAA201506824 A UA A201506824A UA A201506824 A UAA201506824 A UA A201506824A UA 117466 C2 UA117466 C2 UA 117466C2
Authority
UA
Ukraine
Prior art keywords
antibodies
solution formulations
engineered anti
solution
relates
Prior art date
Application number
UAA201506824A
Other languages
English (en)
Inventor
Рамеш С. Каші
Анікет Бадкар
Original Assignee
Мерк Шарп Енд Доме Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117466(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Шарп Енд Доме Корп. filed Critical Мерк Шарп Енд Доме Корп.
Publication of UA117466C2 publication Critical patent/UA117466C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Винахід стосується стабільного складу у вигляді розчину антитіла hum13B8-b до IL-23p19. Винахід також стосується способу лікування аутоімунного, запального або проліферативного захворювання, способу лікування псоріазу та застосування стабільного складу у вигляді розчину у виробництві лікарського препарату.
UAA201506824A 2012-12-13 2013-09-12 СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 UA117466C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (1)

Publication Number Publication Date
UA117466C2 true UA117466C2 (uk) 2018-08-10

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201506824A UA117466C2 (uk) 2012-12-13 2013-09-12 СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Country Status (31)

Country Link
US (2) US20150329632A1 (uk)
EP (1) EP2931313B1 (uk)
JP (1) JP6266012B2 (uk)
KR (1) KR102004585B1 (uk)
CN (1) CN104870016B (uk)
AU (1) AU2013359767B2 (uk)
BR (1) BR112015013540B1 (uk)
CA (1) CA2894869C (uk)
CL (1) CL2015001608A1 (uk)
CY (1) CY1121895T1 (uk)
DK (1) DK2931313T3 (uk)
EA (1) EA034616B1 (uk)
ES (1) ES2732861T3 (uk)
HK (1) HK1215194A1 (uk)
HR (1) HRP20191137T1 (uk)
HU (1) HUE045668T2 (uk)
IL (3) IL278295B2 (uk)
LT (1) LT2931313T (uk)
MX (1) MX357936B (uk)
MY (1) MY187921A (uk)
NZ (1) NZ708443A (uk)
PE (1) PE20151524A1 (uk)
PH (1) PH12015501296B1 (uk)
PL (1) PL2931313T3 (uk)
PT (1) PT2931313T (uk)
RS (1) RS59057B1 (uk)
SI (1) SI2931313T1 (uk)
TR (1) TR201909584T4 (uk)
UA (1) UA117466C2 (uk)
WO (1) WO2014093203A1 (uk)
ZA (1) ZA201504408B (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
TWI775827B (zh) * 2017-03-31 2022-09-01 日商明治製菓藥業股份有限公司 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法
AU2019232624A1 (en) * 2018-03-05 2020-09-10 Janssen Biotech, Inc. Methods of treating Crohn's disease with anti-IL23 specific antibody
US20200155678A1 (en) * 2018-11-21 2020-05-21 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
EP3928101A1 (en) * 2019-02-20 2021-12-29 Amgen Inc. Methods of determining protein stability
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
EP4151233A1 (en) * 2020-05-13 2023-03-22 Innovent Biologics (Suzhou) Co., Ltd. Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
KR20050110628A (ko) 2003-02-10 2005-11-23 엘란 파마슈티칼스, 인크. 면역글로불린 제제 및 이의 제조방법
TWI357336B (en) 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
LT2335725T (lt) * 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
CA2556425A1 (en) 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
RS55788B1 (sr) 2005-08-31 2017-08-31 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
MX2009007406A (es) 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
WO2008103473A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
RS52345B (en) * 2007-02-23 2012-12-31 Schering Corporation ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2205276A4 (en) 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
MX2011002159A (es) * 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
ES2658596T3 (es) * 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
EP2350649A4 (en) * 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
LT2691112T (lt) * 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
CN104159614A (zh) * 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂

Also Published As

Publication number Publication date
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
HUE045668T2 (hu) 2020-01-28
LT2931313T (lt) 2019-09-25
WO2014093203A1 (en) 2014-06-19
HRP20191137T1 (hr) 2019-09-20
IL239150B (en) 2020-11-30
BR112015013540A8 (pt) 2018-04-17
CA2894869A1 (en) 2014-06-19
ZA201504408B (en) 2017-09-27
EA201591133A1 (ru) 2015-10-30
JP2016505572A (ja) 2016-02-25
HK1215194A1 (zh) 2016-08-19
SI2931313T1 (sl) 2019-09-30
IL239150A0 (en) 2015-07-30
US20210188964A1 (en) 2021-06-24
MX357936B (es) 2018-07-31
EP2931313A4 (en) 2016-08-03
BR112015013540B1 (pt) 2021-04-27
EP2931313A1 (en) 2015-10-21
AU2013359767A1 (en) 2015-07-23
IL278295A (uk) 2020-12-31
KR20150092763A (ko) 2015-08-13
PH12015501296A1 (en) 2015-08-24
JP6266012B2 (ja) 2018-01-24
CA2894869C (en) 2021-06-15
EA034616B1 (ru) 2020-02-27
EP2931313B1 (en) 2019-05-08
IL278295B2 (en) 2024-03-01
PE20151524A1 (es) 2015-11-06
CN104870016A (zh) 2015-08-26
CL2015001608A1 (es) 2015-10-30
TR201909584T4 (tr) 2019-07-22
MY187921A (en) 2021-10-28
DK2931313T3 (da) 2019-07-15
BR112015013540A2 (pt) 2017-11-14
NZ708443A (en) 2018-05-25
IL278295B1 (en) 2023-11-01
PL2931313T3 (pl) 2019-10-31
PH12015501296B1 (en) 2015-08-24
AU2013359767B2 (en) 2018-04-05
RS59057B1 (sr) 2019-08-30
KR102004585B1 (ko) 2019-07-26
IL307581A (en) 2023-12-01
CY1121895T1 (el) 2020-10-14
MX2015007213A (es) 2016-08-03
ES2732861T3 (es) 2019-11-26
CN104870016B (zh) 2018-05-08

Similar Documents

Publication Publication Date Title
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
EA201300530A1 (ru) Антитела к il-23
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201401204A1 (ru) Антитела к il-23p19
EA201400579A1 (ru) Антитела к il-36r
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
EA201592203A1 (ru) Способы лечения таупатии
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
PH12016500753B1 (en) Antibodies specific to fcrn
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
EA201492280A1 (ru) Стабильный состав пексиганана